Lab2Market Partners with CPDC to Launch L2M Discover Radiopharma Program
Article by CPDC. Full article is available here.
___
CPDC and Lab2Market (L2M) today announced the L2M Discover Radiopharma program, a groundbreaking initiative to cultivate entrepreneurial skills among Canadian researchers in the radiopharmaceutical sector. Beginning on September 16, 2025, the 10-week virtual training program will equip students and faculty with the foundational tools necessary to embark on their entrepreneurial journey and advance their research toward commercialization.
L2M Discover is an entry-level training program that serves as a stepping stone to the Lab2Market suite of programs, including Validate Foundations, Validate, and Launch. Tailored specifically for researchers in the radiopharmaceutical field, this program aims to bridge the gap between scientific discovery and market impact by cultivating entrepreneurial mindsets and skillsets. With a long-standing relationship with CPDC, McMaster University is the strategic delivery partner for L2M Discover Radiopharma and is well-positioned to lead this program.
“Canada’s universities are at the forefront of radiopharmaceutical research, creating exciting opportunities to develop innovative diagnostics, therapeutics, and enabling technologies with meaningful clinical and commercial impact,” said Owen Roberts, CEO of CPDC. “Through our partnership with Lab2Market, we aim to help scientists translate their research into real-world solutions that ultimately benefit patients.”
“We’re thrilled to be working with CPDC as we launch our first-ever Radiopharma cohort,” said Spencer Giffin, Executive Director, Lab2Market. “Their leadership in radiopharmaceutical innovation aligns perfectly with our mission to empower researchers to explore commercialization pathways. Together, we’re building a stronger ecosystem that accelerates the translation of cutting-edge science into real-world impact across Canada.”
“McMaster is committed to turning world-class research into real-world solutions. By supporting early-stage innovation through programs like Lab2Market, we’re helping researchers take the next step toward commercial success and lasting impact,” said Leigh Wilson, Associate Director, New Ventures, McMaster University.
Application deadline: September 3rd, 11:59pm EST
To learn more and apply: https://www.lab2market.ca/discover
Questions? Please contact Sydney Valentino, Program Manager valens@mcmaster.ca
About CPDC
CPDC is a not-for-profit advancing nuclear medicine in Canada and beyond through strategic investments, expert guidance and innovative radiopharmaceutical development to benefit patients globally. In the past 17 years, CPDC has created four Canadian commercial entities that have accelerated the availability of radiopharmaceuticals to the Canadian and global medical community. CPDC will continue to identify and advance critical radiopharmaceuticals to meet the needs of patients and physicians through our collaborations with partners including industry, academia, and government. For more information on CPDC, visit www.cpdc.ca and follow on LinkedIn.
About Lab2Market
Lab2Market™ envisions Canada as a global leader in transforming academic research into innovative solutions that drive social impact and economic growth. As a national beacon for innovation, commercialization, and entrepreneurship, L2M empowers students, researchers, and highly qualified personnel (HQP) through specialized training that bridges the gap between research and real-world applications. Funded by the Government of Canada, Mitacs, and the Ocean Startup Project, Lab2Market draws inspiration from leading programs such as I-Corps and MIT Delta V (U.S.), ICURe (U.K.), and the Quebec Scientific Entrepreneurship Program. For more information on Lab2Market, visit www.lab2market.ca
Contact
Sydney Valentino
Program Manger, McMaster Industry Liaison Office
valens@mcmaster.ca